Granules India Plans Injectables Acquisition Under $50M

Granules India injectables acquisition plans are taking shape as the drugmaker actively scouts inorganic growth opportunities in the injectables space.

The company is evaluating potential targets with deal sizes capped at around $50 million, signaling a sharp and disciplined M&A approach. Executive Director Priyanka Chigurupati said the focus is on fit, quality, and long-term value rather than scale.

The push into injectables is driven by ongoing global supply shortages and rising quality concerns in the segment. Granules India sees injectables as a logical extension of its existing strengths in oncology and peptide-based products. To support this move, the company plans to set up a dedicated injectables manufacturing facility, possibly outside India, aimed at building a strong quality-led culture and standing apart from competitors.

Also Read: Advancing Interventional Radiology in India Through Collaboration

This strategy also aligns with Granules India’s growing presence in ADHD therapies and CNS opioids, opening doors to more complex injectable formulations. While multiple acquisition candidates are under review, management remains firm on valuation discipline. Funding may come from internal accruals or debt, but the $50 million ceiling will not be crossed.

Beyond the Granules India injectables acquisition strategy, the company continues to invest across its core verticals. Integrated pharma, led by high-volume APIs and KSMs, remains the main cash generator and demands steady capital spending. At the same time, Granules India is deepening its bet on complex generics, seen as the next growth engine, while expanding CDMO services, including liquid peptide synthesis.

Together, targeted acquisitions and focused organic growth position Granules India for steady expansion in a fast-changing global pharma market.